Black Market Steroid Injection Gone Wrong
A 35-year-old healthy man was referred to our emergency room by his physician because of painful skin necrosis over the left buttock approximately 5 × 4 cm and painful skin necrosis with purulent discharge on the right approximately 6.5 × 4 cm (Fig.1).
The patient stated that he is a recreational “body builder” and uses illicit substances to rapidly gain muscle mass. He has been using testosterone and various anabolic steroids for the past 4 years and 3 weeks before his referral changed his regimen to include a new steroid, Trenbolone. He recalled feeling pain upon injection, which led to him injecting more slowly and in an alternating pattern to both gluteus maximus muscles. The patient recalled persistent tenderness and induration in the injection sites followed by “darkening of the skin,” extreme pain, and secretion.
The patient was prescribed a course of first-generation cephalosporin, followed by a course of amoxicillin and clavulanic acid by his physician with no improvement and thereafter was referred to our center.
In the Plastic and Reconstructive Surgery Department, he underwent surgical wound debridement. The necrosis seemed to involve the skin, subcutaneous fat, and a small portion of the gluteus maximus muscle. Wound cultures were positive for Staphylococcus aureus and treated locally with mafenide acetate irrigation and wound dressings. Wound closure options included surgical closure by skin graft, local flaps, or healing by secondary intention. Because of the patient’s concern of further scarring and donor site morbidity, the wound was designated for healing by secondary intention. The patient was discharged with clean wounds and a hydrocolloid dressing 7 days after being admitted to the department. On ambulatory follow-up, the wound healed well with good granulation tissue filling the wound and peripheral epithelialization was observed shrinking the wound on the left to 3.5 × 3 cm and the wound on the right to 5 × 3 cm by 3 weeks after discharge (Figure 2) . At 6 weeks after discharge, wound dressings were changed to polyurethane (Figure 3) and complete epithelialization was observed by 2 months after discharge (Figure 4 ). No complications were noted.
Riley A. Dean, BS,1Adam D. Glener, MD,1Analise B. Thomas, MD,1Steven R. Glener, BS,1Silvia Kurtovic, MD,1 and Detlev Erdmann, MD, PhD, MHSc
1. Thevis M, Schrader Y, Thomas A, et al. Analysis of confiscated black market drugs using chromatographic and mass spectrometric approaches. J Anal Toxicol. 2008;32:232–240. [PubMed] [Google Scholar]
2. Kohler M, Thomas A, Geyer H, et al. Confiscated black market products and nutritional supplements with non-approved ingredients analyzed in the Cologne Doping Control Laboratory 2009. Drug Test Anal. 2010;2:533–537. [PubMed] [Google Scholar]
3. Thevis M, Geyer H, Thomas A, et al. Trafficking of drug candidates relevant for sports drug testing: detection of non-approved therapeutics categorized as anabolic and gene doping agents in products distributed via the Internet. Drug Test Anal. 2011;3:331–336. [PubMed] [Google Scholar]
4. Fotiou F, Aravind S, Wang PP, et al. Impact of illegal trade on the quality of epoetin alfa in Thailand. Clin Ther. 2009;31:336–346. [PubMed] [Google Scholar]
5. Rich JD, Dickinson BP, Feller A, et al. The infectious complications of anabolic-androgenic steroid injection. Int J Sports Med. 1999;20:563–566. [PubMed] [Google Scholar]
6. Raschka C, Chmiel C, Preiss R, et al. [Recreational athletes and doping–a survey in 11 gyms in the area of Frankfurt/Main]. MMW Fortschr Med. 2013;155:57. [PubMed] [Google Scholar]
7. Woerdeman J, de Hon O, Levi M, et al. [Anabolic androgenic steroids in amateur sports in the Netherlands]. Ned Tijdschr Geneeskd. 2010;154:A2004. [PubMed] [Google Scholar]
8. Striegel H, Simon P, Frisch S, et al. Anabolic ergogenic substance users in fitness-sports: a distinct group supported by the health care system. Drug Alcohol Depend. 2006;81:11–19. [PubMed] [Google Scholar]
9. Simon P, Striegel H, Aust F, et al. Doping in fitness sports: estimated number of unreported cases and individual probability of doping. Addiction. 2006;101:1640–1644. [PubMed] [Google Scholar]
10. WADA. The 2014 Prohibited List. Available at: http://www.wada-ama.org/Documents/World_Anti-Doping_Program/WADP-Prohibited-list/2014/WADA-prohibited-list-2014-EN.pdf. Accessed April 24, 2014.11. Krug O, Thomas A, Walpurgis K, et al. Identification of black market products and potential doping agents in Germany 2010-2013. Eur J Clin Pharmacol. 2014;70:1303–13
11. [PubMed] [Google Scholar]
12. Duckett SK, Pratt SL. Meat science and muscle biology symposium—anabolic implants and meat quality. J Anim Sci. 2014;92(1):3–9. [PubMed] [Google Scholar]
13. Köhler LD, Schwedler S, Worret WI. Embolia cutis medicamentosa. Int J Dermatol. 1997;36:197. [PubMed] [Google Scholar]
14. Faucher L, Marcoux D. What syndrome is this? Nicolau syndrome. Pediatr Dermatol. 1995;12:187–190. [PubMed] [Google Scholar]
15. Corazza M, Capozzi O, Virgilit A. Five cases of livedo-like dermatitis (Nicolau’s syndrome) due to bismuth salts and various other non-steroidal anti-inflammatory drugs. J Eur Acad Dermatol Venereol. 2001;15:585–588. [PubMed] [Google Scholar]
16. Lie C, Leung F, Chow SP. Nicolau syndrome following intramuscular diclofenac administration: a case report. J Orthop Surg (Hong Kong) 2006;14:104–107. [PubMed] [Google Scholar]
17. Luton K, Garcia C, Poletti E, et al. Nicolau syndrome: three cases and review. Int J Dermatol. 2006;45:1326–1328. [PubMed] [Google Scholar]
Copyright © 2016 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of The American Society of Plastic Surgeons. All rights reserved.This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.